Low total cellular HER3 expression was demonstrated to find relapsing HER2-amplified breast carcinomas most efficiently; 41.7% (15 of 36) of cases with recurrence were shown to demonstrate low total cellular HER3 expression. Here, ERBB2 is linked to breast carcinoma.